Decentralized disease screening for pandemics and global health

Leveraging capabilities built and lessons learned during the COVID-19 pandemic, along with new AI tools and open source innovations.

Our COVID pandemic testing pilots supported multiple EMS departments, schools, and businesses
“It’s been a godsend. We’re getting so much kudos for having this capability in place when Omicron hit. We immediately scaled up to prevent the spread among our first responders.”
- EMS Training Officer, Bend OR
FloodLAMP Test Training Program
Our Test Training Program is the first of many aspects of FloodLAMP's pandemic work that we are in the process of publishing. The program distills key learnings from deploying rapid COVID surveillance screening services in various configurations. It is primarily aimed at individuals new to laboratory settings, offering comprehensive training on both the technical aspects of molecular testing and the effective management of sites. We've recently added a proof-of-concept custom chatbot to demonstarte what's now possible arising from the transformative capability of the new AI tools.
Learn More
About FloodLAMP
FloodLAMP Biotechnologies is a Public Benefit Corporation founded in 2020. Our mission is to improve public health by facilitating access to rapid molecular testing. The aim is to enable communities, especially those at high risk, to monitor and manage disease spread effectively. Recognizing the crucial role of scalable testing during the COVID-19 pandemic, we developed pilot screening programs under the non-diagnostic "surveillance" framework, as well as pursuing diagnostic EUA authorizations from the FDA, primarily using LAMP test technology. LAMP is a relatively new alternative to the industry-standard PCR and has several advantages over both lab-based PCR and antigen tests. LAMP testing progressed greatly during the pandemic across many modalities and offers great potential for continued development.

Over the last year, the focus of FloodLAMP has shifted from commercial operations and establishing new screening programs to sharing our work, follow-up research, and outreach for future pandemic preparedness and response. Despite the progress on many fronts during the pandemic, we remain vulnerable and would almost certainly experience a severe shortage of testing during the next one. This realization points to an ongoing opportunity for further impactful work, and it is what continues to motivate our work.